Tag: spinal cord stimulation

Nevro Corporation has announced the US Food and Drug Administration (FDA) approval and limited market release of HFX iQ with HFX AdaptivAI—a responsive, personalised...

An international, multicentre study has confirmed the existence of the carryover or ‘echo’ effect—an interval before patients perceive the return of pain after their...

At this year’s North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las Vegas, USA), Medtronic announced new data from two clinical trials demonstrating...

Nevro Corporation has announced a series of data presentations supporting the use of the company's high-frequency (HFX) 10kHz spinal cord stimulation (SCS) therapy for...

As per a recent statement from the North American Neuromodulation Society (NANS), the US state of Washington may be about to extend its insurance...

Nalu Medical has announced the publication of the spinal cord stimulation (SCS) nPower US clinical study in the Pain Physician Journal, reporting on clinical outcomes...

SpineX has reported in a press release that a publication titled, “A pilot study of the effect of transcutaneous spinal cord stimulation on micturition-related...

The principle of medical necessity “should drive all remote monitoring decisions” relating to spinal cord stimulation (SCS) technologies, according to recommendations recently published in...

Biotronik Neuro has announced that results from the BENEFIT-02 trial—the “first of its kind” to clinically evaluate a multiphase stimulation paradigm—support the effectiveness of...

The North American Neuromodulation Society (NANS) has led a multi-society response to the Washington State Health Care Authority (WSHCA) following its review of the...

Onward Medical has today announced the successful first-in-human implant of its ARC-IM stimulator intended to restore upper-extremity function after spinal cord injury (SCI). The...

Nevro Corporation has announced the publication of new data validating the health economic benefits of 10kHz therapy, the company’s proprietary, high-frequency spinal cord stimulation...

Medtronic has received CE-mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator in the treatment of chronic pain. Inceptiv is the first Medtronic spinal...

The neuromodulation space has proliferated significantly over the past few years, and one area in which this is most notable is with the expansion...

Pain physicians have urged the Cochrane Library to retract and revise a recent review of spinal cord stimulation (SCS) in the treatment of low...

Onward Medical has announced a recent publication in Nature showing that a wireless brain-computer interface (BCI) can use patients’ thoughts to modulate ARC therapy....

Abbott has announced that the US Food and Drug Administration (FDA) has approved expanded magnetic resonance imaging (MRI) labelling for its Eterna spinal cord...

Biotronik has announced US Food and Drug Administration (FDA) approval for Prospera—a new spinal cord stimulation (SCS) system. The system features RESONANCE, which the...

Jason Pope (Santa Rosa, USA) discusses closed-loop spinal cord stimulation (SCS) and its potential to provide sustained, holistic outcomes for chronic pain patients. In...

Reach Neuro has been granted a Breakthrough Device designation by the US Food and Drug Administration (FDA) for its Avantis platform, which uses small...

A recently published Cochrane review has concluded that the clinical benefits of spinal cord stimulation (SCS) do not outweigh the risks and costs associated...

NeuroOne Medical Technologies has announced the successful completion of an initial animal implant of its novel, thin-film paddle leads for spinal cord stimulation (SCS)....

Nevro Corporation announced today that it has now initiated the full US market launch of its HFX iQ spinal cord stimulation (SCS) system, following...

Spinal cord stimulation (SCS) therapy has been shown to trigger instant improvements in arm and hand mobility, enabling people affected by moderate-to-severe stroke to...

Spinal cord stimulation (SCS) therapies targeting the dorsal column “may be considered” within the multimodal treatment plans typically required by cancer patients, but it...

Medtronic has announced that it will highlight clinical and preclinical research relating to sensing-enabled spinal cord stimulation (SCS) therapy at the North American Neuromodulation...

Abbott has announced the US Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system, which it claims is...

Saluda Medical has announced plans for a limited commercial release of its Evoke spinal cord stimulation (SCS) system in the USA, with a full commercial...

Despite their clear significance in pain management, gender differences relating to the ways patients respond to neuromodulation therapies are relatively poorly understood and underpinned...

“We are entering an era where true scientific evidence from IONM is guiding technology and our clinical practice.” This was one of the...

Nevro Corporation announced recently that the US Food and Drug Administration (FDA) has approved its manufacturing operations in Costa Rica for the production of its proprietary...

Gimer Medical today announced that the company’s spinal cord stimulation (SCS) system was granted conditional investigational device exemption (IDE) approval by US Food and...

Abbott has announced that the US Food and Drug Administration (FDA) has approved its new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360...

Saluda Medical has announced that Steven Falowski (Argires-Marotti Neurosurgical Associates of Lancaster, Lancaster, USA) recently presented late-breaking 24-month data from the company’s EVOKE study at...

Electrical stimulation technologies, and in particular spinal cord stimulation (SCS) and sphenopalatine ganglion stimulation, offer a promising adjunct to existing therapies for cerebral vasospasm...

Nevro Corporation has announced the results from data presentations at the American Diabetes Association (ADA) 82nd Scientific Sessions (3–7 June 2022, New Orleans, USA) supporting the use of...

Nevro Corporation has announced that data from the SENZA painful diabetic neuropathy (PDN) randomised controlled trial (RCT)—which the company says is the largest RCT to...

A novel approach to spinal cord stimulation (SCS), which involves targeting the dorsal horn dendrite—in contrast with more traditional ‘axonal’ SCS techniques—has been labelled...

Only a small proportion of neuropathic pain patients in England who are potentially eligible for spinal cord stimulation (SCS) have received this intervention over...

Saluda Medical has finalised US$125 million in equity financing, with the proceeds being used in part to operationalise and scale commercialisation of the company’s Evoke spinal...

Following the recent introduction of key data supporting the use of high-frequency spinal cord stimulation (SCS) in the treatment of non-surgical refractory back pain...

Saluda Medical has announced that it has received full approval from the US Food and Drug Administration (FDA) for the Evoke spinal cord stimulation (SCS)...

A spinal cord stimulation (SCS) system capable of simultaneously delivering multiple treatment modalities has produced a sustained improvement in outcomes in a randomised controlled...

Medtronic has received US Food and Drug Administration (FDA) approval of its Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator for the treatment of chronic...

Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...

Medtronic has announced three-month results from an on-label, prospective, multicentre study showing meaningful pain relief using DTM SCS endurance therapy—a modified, lower-energy variation of the...

Wavegate Corporation has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation for its StimuLux optical reflectometry system for closed-loop...

Saluda Medical today announced long-term results from its double-blind, Level 1 EVOKE trial, which have been published in JAMA Neurology and demonstrate superior, sustained pain...

Boston Scientific has announced key data that will be featured at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA)....

Abbott has announced that the US Food and Drug Administration (FDA) has approved new, expanded magnetic resonance imaging (MRI) compatibility for its Proclaim XR spinal cord...

Maricela Schnur (St Luke’s Hospital, Duluth, USA) highlights a handful of socioeconomic disparities, racial differences, and psychological and psychiatric factors, that currently present difficulties...

Passive recharge burst spinal cord stimulation (B-SCS) can alleviate pain intensity and psychological distress, and improve physical function and health-related quality of life out...

Nevro has announced three clinical data publications on treating painful diabetic neuropathy (PDN) with 10kHz spinal cord stimulation (SCS) therapy—including 12-month data from the...

Antibiotic impregnated envelopes appear to be a safe and effective modality for decreasing surgical site infection risks in spinal cord stimulation (SCS) implantation, according...

Nevro Corporation has provided an update on its position following a Delaware jury’s decision to award Boston Scientific US$20 million over patent infringements. The...

NeoSpine is now offering spinal cord stimulation (SCS) procedures for the treatment of painful diabetic neuropathy (PDN) via its HFX system—a newly approved nondrug treatment...

Following the recent approval of the Senza system (Nevro) by the US Food and Drug Administration (FDA), Erika A Petersen (Little Rock, USA) discusses the...

The CRISP (Comparison of paraesthesia mapping to anatomic midline-based burst programming strategies) study, published in Neuromodulation: Technology at the Neural Interface, has found that...

Boston Scientific has announced the European launch of FAST—a new, fast-acting sub-perception therapy that the company says is clinically proven to demonstrate significant and...

Michael Fishman (Wilmington, USA) discusses the benefits of Differential Target Multiplexed spinal cord stimulation (DTM SCS; Medtronic)—when compared to more conventional SCS therapy options—and...

In a randomised pilot study, temporary spinal cord stimulation (SCS) has demonstrated efficacy in the suppression of postoperative atrial fibrillation (AF) following coronary artery...

Nevro has announced receipt of US Food and Drug Administration (FDA) approval for its Senza system for the treatment of chronic pain associated with...

In a study intended to explore gender differences in patients with failed back surgery syndrome (FBSS) or chronic visceral pain, men and women have...

Medtronic has received US Food and Drug Administration (FDA) approval for Vanta—a high-performance, recharge-free implantable neurostimulator (INS) with a device life that can be...

The results of the HALO (High and low frequency options) study, which are published online in the scientific journal Neuromodulation: Technology at the Neural...

 Stephanie Vanterpool (Knoxville, USA) talks to NeuroNews about how outreach can be used to address the disparities between white and underrepresented minority patients when...

A study investigating chronic pain sufferers treated with burst spinal cord stimulation (B-SCS) has concluded that improvements were observed among all psychological measures at...

A spinal cord stimulation (SCS) training curriculum has been developed by a multidisciplinary taskforce of the North American Neuromodulation Society’s (NANS) education committee. It...

Three-month results from a large, multicentre randomised controlled trial (RCT) has demonstrated statistically significant (p=0.0009) and superior back pain relief with differential target multiplexed...

Nevro today announced it has received approval from the US Food and Drug Administration (FDA) for the Senza Omnia spinal cord stimulation (SCS) system....

Abbott has received FDA approval for its Proclaim XR recharge-free neurostimulation system for people with chronic pain. A press release reports that the Proclaim...

Low pain scores after spinal cord stimulation (SCS) trials are predictive of successful SCS implants with high sensitivity, according to a recent study. The...

Stimwave has announced completion of patient enrolment and preliminary results of the first-of-its-kind Tsunami study. The Tsunami placebo-controlled double-blind randomised clinical trial (RCT) is...

Saluda Medical has announced that it has secured a four-year term loan agreement with Medtronic, to fund continued development of its Evoke ECAP-controlled, closed-loop...

Medtronic has announced primary endpoint (three-month) results of the Vectors post-market clinical study that demonstrated effective pain relief and improved function in patients with...

Defining true success as “being able to decrease or even eliminate a patient’s dependency on oral opioids”, Corey W Hunter, founder of Ainsworth Institute...

A multicentre real-world review of 10kHz of spinal cord stimulation (SCS) for the treatment of chronic back and leg pain has elicited positive results,...

The launch of the Spectra WaveWriter spinal cord stimulator (SCS; Boston Scientific) system in Europe has been announced. The Spectra WaveWriter SCS system is...

New results from a multicentre study of Abbott’s BurstDR stimulation show that lower-energy, intermittent doses of BurstDR stimulation—known as “microdosing”—can provide pain relief that is...

Stimwave Technologies has announced that it has received US Food and Drug Administration (FDA) clearance for the WaveCrest Mobile iOS platform patient controllers for...

The Therapeutic Goods Administration (TGA) has granted approval to Nevro for its next-generation Senza II spinal cord stimulation system delivering the company’s proprietary HF10...

Krishnan Chakravarthy writes in NeuroNews about how spinal cord stimulation can be used to treat chronic pain and how this can help America overcome...

A pilot study published in Neuromodulation: Technology at the Neural Interface suggests that high frequency stimulation (HFS), an alternative SCS waveform could also be...

Medtronic has a long-standing commitment to delivering innovative pain stimulation technology and building the evidence that matters today and leads us into the future. This is again...

New data from the WHISPER randomised controlled trial (RCT) have demonstrated that patients who are given the choice to use both sub-perception and paraesthesia-based...

The Spectra WaveWriter Spinal Cord Stimulator (SCS) System (Boston Scientific) has received FDA approval. It is the first and only system approved by the...

The US Food and Drug Administration has approved the next-generation Senza II Spinal Cord Stimulation (SCS) System (Nevro) delivering HF10 therapy. According to the company,...

The first patient has been enrolled in the Vectors Post Market Clinical Study. The study will follow patients with chronic intractable pain who are...

Nevro has received the CE mark for full-body magnetic resonance imaging (MRI) conditional labelling on the Senza Spinal Cord Stimulation (SCS) System delivering HF10...

Medtronic has received CE mark for the Intellis platform for both spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) as an aid in...

With six-month follow-up indicating that dorsal column activation is regulated to therapeutic levels by closed-loop spinal cord stimulation (SCS) using evoked compound action potentials...

The US Food and Drug Administration has approved the Intellis spinal cord stimulation platform (Medtronic) for the management of certain types of chronic intractable...

A randomised controlled trial has found excellent pain relief and no clinical difference among spinal cord stimulation frequencies from 1kHz–10kHz. Further, the study showed...

SafeOp Surgical has filed its tenth patent application for innovations surrounding the monitoring and real-time detection of motor nerve thresholds during surgery. SafeOp developed...

The year 2017 marks the 50th anniversary for spinal cord stimulation therapy which was first used to treat pain in 1967. To celebrate the...

A multicentre retrospective study has found that infection rates associated with spinal cord stimulator implants are lower than previously reported and that these rates...

Saluda Medical, a medical device company developing a platform of closed-loop neuromodulation technologies based on neural response to stimulation, has secured US$40 million in...

CE mark approval has been granted for the world’s first percutaneous injectable anchor system, SandShark. The Stimwave system is used to fixate the company’s...

A study carried out by Kelly Ryan Murphy (Duke University Medical Center, Durham, USA) and colleagues has found that centres with high-volume spinal cord...

Data from a single centre using a single spinal cord stimulator manufacturer have shown that patients with neuropathic pain treated with spinal cord stimulation...

The Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for the Freedom Spinal Cord Stimulation (SCS) System (Stimwave). The company launched the product...

Mayo Clinic (Rochester, USA) researchers have used electrical stimulation on the spinal cord and intense physical therapy to help a man intentionally move his...

A study published in the journal Neuromodulation reports good efficacy with high-frequency spinal cord stimulation with notable reductions on the numerical rating scale back...

A low-profile multicolumn paddle lead has provided an option for spinal cord stimulation therapy in an area which traditionally is difficult to access with...

A multicentre, double-blind, randomised and placebo-controlled crossover trial has found that patients with complex regional pain syndrome (CRPS) show preference for different spinal cord...

At the annual meeting of the Neuromodulation Society of the UK and Ireland (NSUKI; 3–4 November, Manchester, USA) Alan Batterham (Health & Social Care...

While much has been done in the past decade to advance the field of neuromodulation, some investigators believe only small steps have been made...

New research has found spinal cord stimulation therapy can reduce or stabilise the use of opioids in patients battling chronic pain. Researchers examined opioid...

Based on its recent analysis of the spinal cord stimulation (SCS) market, Frost & Sullivan has recognised Nuvectra with the 2017 North American New...

The International Neuromodulation Society (INS) journal Neuromodulation: Technology at the Neural Interface is publishing expert, evidence-based guidance on the safe and efficient use of neuromodulation implants in patient-centred...

The Proclaim Elite spinal cord stimulation (SCS) system (St Jude Medical) has received CE mark approval for full-body magnetic resonance (MR) conditional labelling. With...

Nevro Corp has announced that it has filed a lawsuit for patent infringement against units of Boston Scientific. The lawsuit, filed in the United States...

A recent study explores the safety and efficacy of spinal cord stimulation on gait disturbance in advanced Parkinson’s disease. The investigators found that spinal...

The US Food and Drug Administration (FDA) has approved full-body magnetic resonance (MR) conditional labelling for the Proclaim Elite spinal cord stimulation (SCS) system (St Jude Medical)....

The US Food and Drug Administration (FDA) has approved BurstDR stimulation, a physician-designed form of spinal cord stimulation (SCS) clinically proven to provide superior outcomes for...

A study recently published in the journal Neuromodulation suggests that earlier consideration of spinal cord stimulation in chronic pain care continuum could have a...

In this Boston Scientific Educational Supplement, you will read about the pace of innovation—from delivering the first and only rechargeable spinal cord stimulation (SCS) system powered by intuitive...

Two-year SENZA-RCT results have been published in Neurosurgery, according to Nevro.  The SENZA-RCT is a pivotal study that is both the largest prospective randomised...

Twenty-four month data from a postmarket, clinical registry have found that most patients suffering from chronic pain of the trunk and/or limbs reported “substantial”...

The ability of spinal cord stimulation to affect spike-and-wave discharges has been suggested as a means to mitigate epileptic seizures in recent literature. In...

Blue Cross Blue Shield has denied coverage for high frequency spinal cord stimulation in at least two states. Outposts of the federation of...

Nuvectra has announced the company’s financial results for the first quarter of 2016. According to a press release, total revenue in the first quarter of...

Mainstay Medical International has received CE mark approval for ReActiv8, its proprietary implantable neurostimulation system designed to treat disabling chronic low back pain. According to...

  Boston Scientific Corporation has launched the Precision Montage MRI spinal cord stimulator system after receiving approval from the US Food and Drug Administration (FDA)....

St Jude Medical has announced the US launch and first post-approval implants of the St Jude Medical Axium Neurostimulator System for dorsal root ganglion (DRG) stimulation...

The US Food and Drug Administration (FDA) has approved Medtronic’s Specify SureScan MRI surgical leads, which are indicated for use as part of Medtronic...

With a series of acquisitions and recent product approvals, St. Jude Medical has further solidified its place as a leading provider of treatment options...

By reprogramming existing spinal cord stimulation systems, investigators have been able to restore efficacy in patients who have failed spinal cord stimulation therapy, and...

St Jude Medical’s Burst stimulation can relieve chronic pain more effectively than traditional tonic spinal cord stimulation (SCS), according to the SUNBURST study. The...

Final results evaluating the Precision Spectra spinal cord stimulator system (Boston Scientific) demonstrate that the device provides more than 70% greater low back pain...

St Jude Medical has launched its Proclaim Elite spinal cord stimulation (SCS) system in Europe. According to a press release, this is the world’s...

St Jude Medical has announced FDA approval of the new Proclaim Elite Spinal Cord Stimulation System, the first and only upgradeable and recharge-free spinal cord stimulation (SCS)...

St Jude Medical has received CE mark approval for magnetic resonance imaging (MRI) conditional labelling for the company’s Prodigy MRI chronic pain system with...

St Jude Medical has received Food and Drug Administration (FDA) approval of the Invisible Trial System. The system, which received CE mark in June...

Now complete, the acquisition of Spinal Modulation adds DRG stimulation technology to the St Jude Medical chronic pain portfolio.

Following the completion of this acquisition, St Jude Medical will become the only medical device manufacturer to offer radiofrequency ablation (RFA), spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation therapy solutions for the treatment of chronic pain.